Skip to main content

Baxter International Value Stock - Dividend - Research Selection

Baxter international

ISIN: US0718131099 , WKN: 853815

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Baxter International Inc. provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. It offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies. The company also provides biological products and medical devices, and surgical hemostat and sealant products used in surgical procedures for hemostasis, tissue sealing, and adhesion prevention; premixed and oncology drug platforms, inhaled anesthesia and critical care products, and pharmacy compounding services; and generic injectable pharmaceuticals. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors\' offices, and by patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was founded in 1931 and is headquartered in Deerfield, Illinois.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


MediThinQ and Synovis Micro Companies Alliance, Inc. Announce Strategic Global Distribution Agreement to Redefine Microsurgery with the SHIYA 3D Visualization Platform

2026-06-18
MediThinQ, a South Korea-based innovator in surgical visualization technologies, has entered into an exclusive multi-year distribution agreement with Synovis Micro Companies Alliance, Inc. ("Synovis MCA"), a subsidiary of Baxter International Inc. (NYSE:BAX) and trusted leader in microsurgical devices and solutions, to commercialize SHIYA, its 3D surgical visualization platform. Terms of this agreement were not disclosed.

Is Baxter International Stock Underperforming the S&P 500?

2026-06-17
Due to Baxter International's underperformance relative to the S&P 500 over the past year, Wall Street analysts maintain a cautious outlook on the stock’s prospects.

Reasons to Retain Baxter International Stock in Your Portfolio for Now

2026-06-16
BAX is pursuing a broad turnaround as innovation, resilient demand, and AI integration support recovery despite regulatory risks and margin pressure.

Baxter (BAX) Stock After Recent Rebound Is The Discount To DCF Value Warranted

2026-06-15
Wondering whether Baxter International at US$20.86 is a bargain or a value trap? This article breaks down what the current share price might be telling you about the stock. The stock has risen 7.6% over the past week and 20.6% over the past month, yet is still down 7.0% year to date and has declined 31.3% over the last year. This raises questions about how the market now views its risk and potential. Recent coverage has focused on Baxter International's position within the medical equipment...

Baxter International (BAX) Stock Valuation Check After Recent Double Digit Gains And Ongoing Turnaround Plans

2026-06-14
Baxter International (BAX) has attracted fresh attention after recent trading, with the stock showing double digit returns over the past month and past 3 months. This performance is prompting investors to reassess its current valuation. See our latest analysis for Baxter International. The recent move takes Baxter International's share price to US$20.86, with share price returns of 20.58% over 30 days and 22.13% over 90 days, while the 1 year total shareholder return has declined 31.29%. This...

3 Unpopular Stocks We’re Skeptical Of

2026-06-12
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.

Is Baxter International Inc. (BAX) A Good Stock To Buy Now?

2026-06-11
Is BAX a good stock to buy? We came across a bullish thesis on Baxter International Inc. on Heavy Moat Investments’s Substack. In this article, we will summarize the bulls’ thesis on BAX. Baxter International Inc.’s share was trading at $20.03 as of June 9th. BAX’s forward P/E was 10.20 according to Yahoo Finance. Baxter International (BAX) […]

FDA Issues Early Alert Regarding Pressure Breathing Device Issue from Baxter

2026-06-11
https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/early-alert-positive-pressure-breathing-device-issue-baxter

DaVita Stock Gains From Integrated Kidney Care and CKCC Progress

2026-06-10
DVA expands its IKC platform, tops CKCC savings in first-quarter 2026 and rolls out AI ScheduleHub to boost scheduling and staffing.

Baxter International (BAX) Faces Tough Road Ahead, Says Citi in Downgrade

2026-06-10
With a TTM operating cash flow of $1.25 billion, Baxter International Inc. (NYSE:BAX) is included among the 12 Cash-Rich Stocks to Buy Right Now. On May 28, Citi analyst Joanne Wuensch downgraded Baxter International Inc. (NYSE:BAX) to Sell from Neutral. She lowered the price target on the stock to $17 from $19. In a research note, the […]